212 related articles for article (PubMed ID: 22653791)
1. PET and MRI reveal early evidence of neurodegeneration in spinocerebellar ataxia type 17.
Brockmann K; Reimold M; Globas C; Hauser TK; Walter U; Machulla HJ; Rolfs A; Schöls L
J Nucl Med; 2012 Jul; 53(7):1074-80. PubMed ID: 22653791
[TBL] [Abstract][Full Text] [Related]
2. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism.
Kim JM; Hong S; Kim GP; Choi YJ; Kim YK; Park SS; Kim SE; Jeon BS
Arch Neurol; 2007 Oct; 64(10):1510-8. PubMed ID: 17923635
[TBL] [Abstract][Full Text] [Related]
3. No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
Schöls L; Reimold M; Seidel K; Globas C; Brockmann K; Hauser TK; Auburger G; Bürk K; den Dunnen W; Reischl G; Korf HW; Brunt ER; Rüb U
Brain; 2015 Nov; 138(Pt 11):3316-26. PubMed ID: 26362908
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.
Jacobi H; Reetz K; du Montcel ST; Bauer P; Mariotti C; Nanetti L; Rakowicz M; Sulek A; Durr A; Charles P; Filla A; Antenora A; Schöls L; Schicks J; Infante J; Kang JS; Timmann D; Di Fabio R; Masciullo M; Baliko L; Melegh B; Boesch S; Bürk K; Peltz A; Schulz JB; Dufaure-Garé I; Klockgether T
Lancet Neurol; 2013 Jul; 12(7):650-8. PubMed ID: 23707147
[TBL] [Abstract][Full Text] [Related]
5. PET and MRI detection of early and progressive neurodegeneration in spinocerebellar ataxia type 36.
Aguiar P; Pardo J; Arias M; Quintáns B; Fernández-Prieto M; Martínez-Regueiro R; Pumar JM; Silva-Rodríguez J; Ruibal Á; Sobrido MJ; Cortés J
Mov Disord; 2017 Feb; 32(2):264-273. PubMed ID: 27862279
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic function in spinocerebellar ataxia type 6 patients with and without parkinsonism.
Horimoto Y; Hayashi E; Ito Y; Iida A; Goto Y; Kato S; Okita K; Kako T; Sato C; Tajima T; Inagaki A; Nokura K; Hibino H; Matsukawa N; Yamada K; Kabasawa H
J Neurol; 2020 Sep; 267(9):2692-2696. PubMed ID: 32440919
[TBL] [Abstract][Full Text] [Related]
7. Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17).
Lasek K; Lencer R; Gaser C; Hagenah J; Walter U; Wolters A; Kock N; Steinlechner S; Nagel M; Zühlke C; Nitschke MF; Brockmann K; Klein C; Rolfs A; Binkofski F
Brain; 2006 Sep; 129(Pt 9):2341-52. PubMed ID: 16760196
[TBL] [Abstract][Full Text] [Related]
8. Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism.
Kono S; Ouchi Y; Terada T; Ida H; Suzuki M; Miyajima H
Mov Disord; 2010 Sep; 25(12):1823-9. PubMed ID: 20669267
[TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6.
Wüllner U; Reimold M; Abele M; Bürk K; Minnerop M; Dohmen BM; Machulla HJ; Bares R; Klockgether T
Arch Neurol; 2005 Aug; 62(8):1280-5. PubMed ID: 16087769
[TBL] [Abstract][Full Text] [Related]
10. The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment.
Lin IS; Wu RM; Lee-Chen GJ; Shan DE; Gwinn-Hardy K
Parkinsonism Relat Disord; 2007 May; 13(4):246-9. PubMed ID: 16793320
[TBL] [Abstract][Full Text] [Related]
11. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.
Ciarmiello A; Cannella M; Lastoria S; Simonelli M; Frati L; Rubinsztein DC; Squitieri F
J Nucl Med; 2006 Feb; 47(2):215-22. PubMed ID: 16455626
[TBL] [Abstract][Full Text] [Related]
12. Structural changes associated with progression of motor deficits in spinocerebellar ataxia 17.
Reetz K; Lencer R; Hagenah JM; Gaser C; Tadic V; Walter U; Wolters A; Steinlechner S; Zühlke C; Brockmann K; Klein C; Rolfs A; Binkofski F
Cerebellum; 2010 Jun; 9(2):210-7. PubMed ID: 20016963
[TBL] [Abstract][Full Text] [Related]
13. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain.
Casteels C; Vermaelen P; Nuyts J; Van Der Linden A; Baekelandt V; Mortelmans L; Bormans G; Van Laere K
J Nucl Med; 2006 Nov; 47(11):1858-66. PubMed ID: 17079820
[TBL] [Abstract][Full Text] [Related]
14. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6.
Reetz K; Costa AS; Mirzazade S; Lehmann A; Juzek A; Rakowicz M; Boguslawska R; Schöls L; Linnemann C; Mariotti C; Grisoli M; Dürr A; van de Warrenburg BP; Timmann D; Pandolfo M; Bauer P; Jacobi H; Hauser TK; Klockgether T; Schulz JB;
Brain; 2013 Mar; 136(Pt 3):905-17. PubMed ID: 23423669
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Preclinical Neuroimaging Changes in Spinocerebellar Ataxia Type 12: A Study of Three Chinese Pedigrees.
Yao T; Qiao H; Sun J; Li X; Song Y; Xu F; Gao L; Zhang D; Yan Z; Ye C; Lai H; Liang Z; Wu T; Wang CD
Eur Neurol; 2022; 85(6):467-477. PubMed ID: 35853433
[TBL] [Abstract][Full Text] [Related]
16. Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia.
Oh JS; Oh M; Chung SJ; Kim JS
Neuroreport; 2014 Oct; 25(15):1198-202. PubMed ID: 25144395
[TBL] [Abstract][Full Text] [Related]
17. Cognitive dysfunction, social behavior disorder, cerebellar ataxia, and atypical brain FDG-PET presentation in spinocerebellar ataxia 17: a case report.
Grassini A; Cermelli A; Roveta F; Zotta M; Lesca A; Marcinnò A; Ferrandes F; Piella E; Boschi S; Lombardo C; Brusco A; Gallone S; Rubino E; Bruni A; Rainero I
Neurol Sci; 2024 Jun; 45(6):2877-2880. PubMed ID: 38494459
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography and magnetic resonance imaging in spinocerebellar ataxia type 2: a study of symptomatic and asymptomatic individuals.
Inagaki A; Iida A; Matsubara M; Inagaki H
Eur J Neurol; 2005 Sep; 12(9):725-8. PubMed ID: 16128876
[TBL] [Abstract][Full Text] [Related]
19. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
Adams JR; van Netten H; Schulzer M; Mak E; Mckenzie J; Strongosky A; Sossi V; Ruth TJ; Lee CS; Farrer M; Gasser T; Uitti RJ; Calne DB; Wszolek ZK; Stoessl AJ
Brain; 2005 Dec; 128(Pt 12):2777-85. PubMed ID: 16081470
[TBL] [Abstract][Full Text] [Related]
20. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study.
Miyoshi M; Shinotoh H; Wszolek ZK; Strongosky AJ; Shimada H; Arakawa R; Higuchi M; Ikoma Y; Yasuno F; Fukushi K; Irie T; Ito H; Suhara T
Parkinsonism Relat Disord; 2010 Jul; 16(6):404-8. PubMed ID: 20452812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
